WuXi Biologics
Shanghai, CN · Wuxi, CN
Compare CAR-T CDMOs in Asia
Compare CAR-T CDMOs in China
Compare Cell Therapy CDMOs in Asia
Compare Cell Therapy CDMOs in China
Compare AAV CDMOs in Asia
Compare AAV CDMOs in China
Compare ADC CDMOs in Asia
Compare ADC CDMOs in China
Program data pending ClinicalTrials.gov matching
· Last scored 2026-10-29
82.7
Signal Score
✓ FDA Inspections (1)
○ Clinical Trials
○ SEC Filings
✓ Press (20)
✓ EMA GMP (3)
✓ MHRA GMP (1)
✓ HC GMP (2)
Quick Facts: WuXi Biologics
- Signal Score
- 82.7/100 (as of 2026-10-29)
- Quality Compliance
- 99.6/100 — Clean EMA record: 3 active GMP certificates (no deductions)
- Headquarters
- Shanghai, CN · Wuxi, CN
- Modalities
- CAR-T, Cell Therapy, AAV, ADC, Monoclonal Antibody
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About WuXi Biologics
Pure-play CDMO.
Signal Score & Pillar Breakdown
Quality Compliance
99.6
Clean EMA record: 3 active GMP certificates (no deductions)
Sources: FDA Data Dashboard, EMA EudraGMDP, MHRA GMDP
Clean EMA record: 3 active GMP certificates (no deductions)
FDA Inspections1 on record
Warning Letters0
Last InspectionVoluntary Action Indicated (VAI) (2026-07-03)
EMA GMP Certificates3 on record
MHRA GMP Certificates1 on record
Most Recent HC OutcomeCompliant · 2024-10-11
HC Attribution2 company-level
Source: Health Canada Drug and Health Product Inspections Database. Ratings shown in Health Canada's own vocabulary; not equivalent to FDA classifications. Company-level records are attributed by the regulator's published establishment name, not by a verified site identifier. Contains information licensed under the Open Government Licence – Canada.
Clean EMA record: 3 active GMP certificates (no deductions)
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesCAR-T, Cell Therapy, AAV, ADC, Monoclonal Antibody
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Scored from ClinicalTrials.gov and FDA records; SEC EDGAR and press items are shown as company signals, not scored. No unverified estimates shown.
Financial Stability
68.0
Parent company: WuXi AppTec
Financial assessment: 68.0/100
Source: company profile (public/private status, parent company)
Profile-based financial assessment
SEC FilingsPrivate company
Parent company: WuXi AppTec
Financial assessment: 68.0/100
Capacity
68.0
3 manufacturing sites
Broad modality coverage (5 modalities)
Sites: Shanghai, CN, Wuxi, CN, Dundalk, IE
Source: company profiles (manufacturing sites, modality breadth)
3 manufacturing sites
Press Signals20 articles (not scored)
3 manufacturing sites
Broad modality coverage (5 modalities)
WuXi Biologics FDA Inspection History
2026-07
NAI
VAI
OAI
| Date | Site | Type | 483 citations posted | Classification |
|---|---|---|---|---|
| 2026-07-03 |
Wuxi Biologics Co Ltd
Wuxi
Company-level
|
Drug Quality Assurance | Not posted | Voluntary Action Indicated (VAI) |
Source: FDA Data Dashboard · Retrieved Nov 21, 2026
WuXi Biologics EMA GMP Compliance 3 certificates
2024-10
2024-10
2024-08
Compliant
Non-Compliant
| Certificate | Site | Country | Inspection Date | Status |
|---|---|---|---|---|
| 35282/IMP13104/00001 | Wuxi Biologics Ireland Limited | Ireland | 2024-10-11 | COMPLIANT |
| 35282/M13105/00001 | Wuxi Biologics Ireland Limited | Ireland | 2024-10-11 | COMPLIANT |
| DE_NW_03_GMP_2025_0079 | WuXi Biologics Germany GmbH | Germany | 2024-08-23 | COMPLIANT |
Source: EMA EudraGMDP · Retrieved Nov 21, 2026
WuXi Biologics MHRA GMP Compliance 1 certificates
2025-08
Compliant
Non-Compliant
| Certificate | Site | City / Postcode | Inspection Date | Status |
|---|---|---|---|---|
| UK GMP 52290 Insp GMP 52290/19113162-0001[H] | WUXI BIOLOGICS CO LIMITED | CN-214092 | 2025-08-12 | COMPLIANT |
Source: MHRA GMDP Database · Retrieved Nov 21, 2026
Japan-accredited overseas site (PMDA)
biologics · 2 sites
- Wuxi, China · WuXi Biologics Co., Ltd. — biologics · valid to Jul 30, 2031
- Dundalk, Ireland · WuXi Biologics Ireland Limited — biologics · valid to May 27, 2031
PMDA accreditation of a foreign manufacturing site is recognition within Japan's regulatory system, not an inspection outcome. PMDA's list covers only manufacturing sites outside Japan, so a company's plants in Japan are not on it. Source: PMDA, list of accredited/registered foreign manufacturers (as of Oct 16, 2026), Public Data License 1.0 (terms)
Hiring Activity Beta
Built from public job postings when a company's own roles can be read. Job postings are signals, not statements by the company; each one below links to the original. How we collect this
No hiring data. This company's careers site asks automated readers not to collect it (robots.txt), and we respect that.
Source:
public careers pages
· Checked Nov 20, 2026
Company Signals 20 articles
Company announcements, not verified evidence. They do not change any score.
WuXi Biologics breaks ground on CRDMO center in Singapore - Singapore Economic Development Board (EDB)
WuXi Biologics breaks ground on CRDMO center in Singapore Singapore Economic Development Board (EDB)
What WuXi Biologics Buyers Were Betting On - Simply Wall Street
What WuXi Biologics Buyers Were Betting On Simply Wall Street
WuXi Biologics at Festival of Biologics Basel 2026: Turning Scientific Complexity Into Commercial Certainty - Moomoo
WuXi Biologics at Festival of Biologics Basel 2026: Turning Scientific Complexity Into Commercial Certainty Moomoo
WuXi Biologics Continues to Be Included in Multiple Hang Seng Sustainability Indexes, Demonstrating ESG Excellence - PR Newswire
WuXi Biologics Continues to Be Included in Multiple Hang Seng Sustainability Indexes, Demonstrating ESG Excellence PR Newswire
WuXi Biologics at CPHI Milan 2026: Empowering Biomanufacturing in Europe - PR Newswire
WuXi Biologics at CPHI Milan 2026: Empowering Biomanufacturing in Europe PR Newswire
How FDA Inspection Success At WuXi Biologics Stock Has Changed Its Investment Story - Simply Wall Street
How FDA Inspection Success At WuXi Biologics Stock Has Changed Its Investment Story Simply Wall Street
WuXi Biologics Releases 2025 Sustainability Report, Advancing Sustainable Growth and Improving Healthcare Access - The Manila Times
WuXi Biologics Releases 2025 Sustainability Report, Advancing Sustainable Growth and Improving Healthcare Access The Manila Times
Assessing WuXi Biologics (SEHK:2269) Valuation As Undervaluation Narrative Gains Traction - simplywall.st
Assessing WuXi Biologics (SEHK:2269) Valuation As Undervaluation Narrative Gains Traction simplywall.st
Assessing WuXi Biologics (SEHK:2269) Valuation As Undervaluation Narrative Gains Traction - simplywall.st
Assessing WuXi Biologics (SEHK:2269) Valuation As Undervaluation Narrative Gains Traction simplywall.st
WuXi Biologics Secures MFDS GMP Certification For Three Key Manufacturing Facilities - BioPharma APAC
WuXi Biologics Secures MFDS GMP Certification For Three Key Manufacturing Facilities BioPharma APAC
WuXi Biologics Completes Structure of Chengdu Microbial Manufacturing Site - Contract Pharma
WuXi Biologics Completes Structure of Chengdu Microbial Manufacturing Site Contract Pharma
WuXi Biologics Chengdu Microbial Commercial Manufacturing Site Achieves Structural Completion and Key Equipment Arrival - Yahoo! Finance Canada
WuXi Biologics Chengdu Microbial Commercial Manufacturing Site Achieves Structural Completion and Key Equipment Arrival Yahoo! Finance Canada
WuXi Biologics Chengdu Microbial Commercial Manufacturing Site Achieves Structural Completion and Key Equipment Arrival - Yahoo Finance
WuXi Biologics Chengdu Microbial Commercial Manufacturing Site Achieves Structural Completion and Key Equipment Arrival Yahoo Finance
WuXi Biologics Achieves Structural Completion and Key Equipment Arrival At Chengdu Microbial Commercial Manufacturing Site - marketscreener.com
WuXi Biologics Achieves Structural Completion and Key Equipment Arrival At Chengdu Microbial Commercial Manufacturing Site marketscreener.com
WuXi Biologics Receives South Korea MFDS GMP Certification to Enable Commercial Manufacturing of Bispecific Antibody Therapeutics - Eastern Progress
WuXi Biologics Receives South Korea MFDS GMP Certification to Enable Commercial Manufacturing of Bispecific Antibody Therapeutics Eastern Progress
WuXi Biologics Receives South Korea MFDS GMP Certification to Enable Commercial Manufacturing of Bispecific Antibody Therapeutics - marketscreener.com
WuXi Biologics Receives South Korea MFDS GMP Certification to Enable Commercial Manufacturing of Bispecific Antibody Therapeutics marketscreener.com
WuXi Biologics Secures MFDS GMP Certification For Three Key Manufacturing Facilities - BioPharma APAC
WuXi Biologics Secures MFDS GMP Certification For Three Key Manufacturing Facilities BioPharma APAC
WuXi Biologics Receives South Korea MFDS GMP Certification to Enable Commercial Manufacturing of Bispecific Antibody Therapeutics - The Manila Times
WuXi Biologics Receives South Korea MFDS GMP Certification to Enable Commercial Manufacturing of Bispecific Antibody Therapeutics The Manila Times
WuXi Biologics Secures MFDS GMP Certification For Three Key Manufacturing Facilities - BioPharma APAC
WuXi Biologics Secures MFDS GMP Certification For Three Key Manufacturing Facilities BioPharma APAC
WuXi Biologics Receives South Korea MFDS GMP Certification to Enable Commercial Manufacturing of Bispecific Antibody Therapeutics - Yahoo Finance
WuXi Biologics Receives South Korea MFDS GMP Certification to Enable Commercial Manufacturing of Bispecific Antibody Therapeutics Yahoo Finance
Frequently Asked Questions About WuXi Biologics
How many FDA inspections does WuXi Biologics have on record?
CDMO Signal tracks 1 FDA inspection for WuXi Biologics, sourced from the FDA inspection database. See the full inspection history above.
Has WuXi Biologics received an FDA warning letter?
CDMO Signal has no FDA warning letters on record for WuXi Biologics.
Does WuXi Biologics hold EMA or MHRA GMP certificates?
CDMO Signal tracks 3 EMA and 1 MHRA GMP certificates for WuXi Biologics.
What is WuXi Biologics's CDMO Signal Score?
WuXi Biologics has a Signal Score of 83/100, based on quality, operations, financial stability, and capacity data.
Evaluating WuXi Biologics for a manufacturing program?
Use the free AI matchmaker to compare WuXi Biologics against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
AGC Biologics
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
Signal Score: 79.9
CAR-T, Cell Therapy, AAV, Lentiviral, ADC, Monoclonal Antibody, Recombinant Protein, Microbial Fermentation
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 86.3
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral, ADC
Lonza
Basel, Switzerland
Signal Score: 72.8
AAV, Lentiviral, Cell Therapy, mRNA, ADC, Monoclonal Antibody, Recombinant Protein, Microbial Fermentation, Small Molecule API, High-Potency APIs, Oral Solid Dose
Rose BioSolutions
Rockville, MD · Memphis, TN · Keele, United Kingdom
Signal Score: 64.0
AAV, Lentiviral, Adenoviral, Plasmid, Cell Therapy, CAR-T
Catalent
Tampa, FL
Signal Score: 76.1
Monoclonal Antibody, Recombinant Protein, ADC, AAV, mRNA, Plasmid DNA, Fill-Finish
Compare WuXi Biologics with another CDMO
Side-by-side scoring, FDA inspection history, EMA/MHRA GMP coverage, and clinical-program footprint.